Categories
Prostate cancer

Is time to castration resistant prostate cancer a potential intermediate end-point for time to metastasis among men initiating androgen deprivation therapy for non-metastatic prostate cancer with rapid PSA doubling time (

  • Moreira DM, Howard LE, Sourbeer KN, Amarasekara HS, Chow LC, Cockrell DC, et al. Predicting time from metastasis to overall survival in castration-resistant prostate cancer: results from SEARCH. Clin Genitourin Cancer. 2017;15:60–66.

    Article 

    Google Scholar
     

  • Xie W, Regan MM, Buyse M, Halabi S, Kantoff PW, Sartor O, et al. Metastasis-free survival is a strong surrogate of overall survival in localized prostate cancer. J Clin Oncol. 2017;35:3097–104.

    CAS 
    Article 

    Google Scholar
     

  • Xie W, Regan MM, Buyse M, Halabi, Kantoff PW, Sartor O, et al. Event-free survival, a prostate-specific antigen-based composite end point, is not a surrogate for overall survival in men with localized prostate cancer treated with radiation. J Clin Oncol. 2020;38:3032–41.

  • Gharzai LA, Jiang R, Wallington D, Jones G, Birer S, Jairath N, et al. Intermediate clinical endpoints for surrogacy in localised prostate cancer: an aggregate meta-analysis. Lancet Oncol. 2021;22:402–10.

    Article 

    Google Scholar
     

  • Hussain M, Fizazi K, Saad F, Rathenborg P, Shore N, Ferreira U, et al. Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer. N. Engl J Med. 2018;378:2465–74.

    CAS 
    Article 

    Google Scholar
     

  • Smith MR, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Graff JN, et al. Apalutamide treatment and metastasis-free survival in prostate cancer. N. Engl J Med. 2018;378:1408–18.

    CAS 
    Article 

    Google Scholar
     

  • Fizazi K, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S, et al. Darolutamide in nonmetastatic, castration-resistant prostate cancer. N Engl J Med. 2019;380:1235–46.

  • Whitney CA, Howard LE, Freedland SJ, De Hoedt AM, Amling CL, Aronson WJ, et al. Impact of age, comorbidity, and PSA doubling time on long-term competing risks for mortality among men with non-metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2019;22:252–60.

    Article 

    Google Scholar
     

  • Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, Walsh PC, et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA. 2005;294:433–9.

    CAS 
    Article 

    Google Scholar
     

  • Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, Walsh PC, et al. Death in patients with recurrent prostate cancer after radical prostatectomy: prostate-specific antigen doubling time subgroups and their associated contributions to all-cause mortality. J Clin Oncol. 2007;25:1765–71.

    Article 

    Google Scholar
     

  • Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol. 2008;26:1148–59.

    Article 

    Google Scholar
     

  • Akoglu H. User’s guide to correlation coefficients. Turk J Emerg Med. 2018;18:91–93.

    Article 

    Google Scholar
     

  • Weier DR, Basu AP. An investigation of Kendall’s tau modified for censered data with applications. J Stat Plan Inference. 1980;4:381–90.

    Article 

    Google Scholar
     

  • Kim Y, Lim J, Park D. Testing independence of bivariate interval-censored data using modified Kendall’s tau statistic. Biometrical J. 2015;57:1131–45.

    Article 

    Google Scholar
     

  • Smith MR, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Graff JN, et al. Apalutamide and overall survival in prostate cancer. Eur Urol. 2021;79:150–8.

    CAS 
    Article 

    Google Scholar
     

  • Sternberg CN, Fizazi K, Saad F, Shore ND, De Giorgi U, Penson DF, et al. Enzalutamide and survival in nonmetastatic, castration-resistant prostate cancer. N. Engl J Med. 2020;382:2197–206.

    CAS 
    Article 

    Google Scholar
     

  • Fizazi K, Shore N, Tammela TL, Ulys A, Fjaters E, Polyakov S, et al. Nonmetastatic, castration-resistant prostate cancer and survival with darolutamide. N. Engl J Med. 2020;383:1040–9.

    CAS 
    Article 

    Google Scholar
     

  • Schweizer MT, Huang P, Kattan MW, Kibel AS, de Wit R, Sternberg CN, et al. Adjuvant leuprolide with or without docetaxel in patients with high-risk prostate cancer after radical prostatectomy (TAX-3501): important lessons for future trials. Cancer. 2013;119:3610–8.

    CAS 
    Article 

    Google Scholar
     

  • Hofman MS, Lawrentschuk N, Francis RJ, Tang C, Vela I, Thomas P, et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multi-centre study. Lancet. 2020;395:1208–16.

    CAS 
    Article 

    Google Scholar
     

  • Leave a Reply